「18F」FMCH PET/CT生物标志物与相似性分析优化寡转移性前列腺癌定义
该前瞻性观察性试验纳入92例根治性治疗后生化失败的前列腺癌患者,行「18F」FMCH PET/CT并分析病灶相似性。以3病灶为阈值时38例为寡转移、54例为多转移;以5病灶为阈值时寡转移增至60例。5病灶阈值下寡转移患者病灶异质性与多转移患者相当,而3病灶阈值下寡转移患者异质性较低;作者支持采用3病灶阈值定义寡转移性前列腺癌。
要点
- 「18F」FMCH PET/CT共识别370个病灶,按解剖分为区域淋巴结和远处转移。
- 3病灶阈值定义寡转移38例、多转移54例;5病灶阈值下寡转移增至60例。
- 5病灶阈值下寡转移患者病灶异质性与多转移患者相当。
核心结论
- 以5病灶为阈值定义的寡转移患者与多转移患者病灶异质性相当,而以3病灶为阈值定义的寡转移患者异质性低于多转移患者,两组呈现不同细胞表型。
- 作者认为结果支持采用3病灶阈值定义寡转移性前列腺癌。
研究设计与样本
- 前瞻性观察性试验,纳入一线根治性治疗后生化失败、符合「18F」FMCH PET/CT检查条件的前列腺癌患者。
- 对92例患者的PET/CT图像进行视觉与定量分析,并按检出病灶总数分类为寡转移或多转移。
- 采用3病灶阈值(≤3 vs >3)和5病灶阈值(≤5 vs >5)两种寡转移定义进行比较,并进行单因素分析和患者内病灶相似性分析。
主要发现
- 「18F」FMCH PET/CT共识别370个病灶,解剖上分为区域淋巴结和远处转移。
- 按3病灶阈值,38例为寡转移、54例为多转移;按5病灶阈值,寡转移增至60例、多转移为32例。
- 相似性分析显示病灶异质性高;按转移灶数目分组后,5病灶阈值定义的寡转移患者病灶异质性与多转移患者相当。
- 3病灶阈值定义的肿瘤负荷有限患者,其病灶异质性较低。
关键数值与推荐
- 寡转移定义之一:检出病灶总数≤3为寡转移、>3为多转移,对应寡转移38例、多转移54例。
- 寡转移定义之二:检出病灶总数≤5为寡转移、>5为多转移,对应寡转移60例、多转移32例。
- 相似性分析显示高病灶异质性;5病灶阈值寡转移患者异质性与多转移患者相当,3病灶阈值寡转移患者异质性较低。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The role of image-derived biomarkers in recurrent oligometastatic Prostate Cancer (PCa) is unexplored. This paper aimed to evaluate [18F]FMCH PET/CT radiomic analysis in patients with recurrent PCa after primary radical therapy. Specifically, we tested intra-patient lesions similarity in oligometastatic and plurimetastatic PCa, comparing the two most used definitions of oligometastatic disease. METHODS: PCa patients eligible for [18F]FMCH PET/CT presenting biochemical failure after first-line curative treatments were invited to participate in this prospective observational trial. PET/CT images of 92 patients were visually and quantitatively analyzed. Each patient was classified as oligometastatic or plurimetastatic according to the total number of detected lesions (up to 3 and up to 5 or > 3 and > 5, respectively). Univariate and intra-patient lesions' similarity analysis were performed. RESULTS: [18F]FMCH PET/CT identified 370 lesions, anatomically classified as regional lymph nodes and distant metastases. Thirty-eight and 54 patients were designed oligometastatic and plurimetastatic, respectively, using a 3-lesion threshold. The number of oligometastic scaled up to 60 patients (thus 32 plurimetastatic patients) with a 5-lesion threshold. Similarity analysis showed high lesions' heterogeneity. Grouping patients according to the number of metastases, patients with oligometastatic PCa defined with a 5-lesion threshold presented lesions heterogeneity comparable to plurimetastic patients. Lesions within patients having a limited tumor burden as defined by three lesions were characterized by less heterogeneity. CONCLUSIONS: We found a comparable heterogeneity between patients with up to five lesions and plurimetastic patients, while patients with up to three lesions were less heterogeneous than plurimetastatic patients, featuring different cells phenotypes in the two groups. Our results supported the use of a 3-lesion threshold to define oligometastatic PCa.
引用
- Sollini M, Bartoli F, Cavinato L, et al. [18F]FMCH PET/CT biomarkers and similarity analysis to refine the definition of oligometastatic prostate cancer. EJNMMI Res. 2021. PMID: 34837532. doi:10.1186/s13550-021-00858-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。